NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer

Maija Wolf (Corresponding Author), Henrik Edgren, Aslaug Muggerud, Sami Kilpinen, Pia Huusko, Therese Sørlie, Spyro Mousses, Olli Kallioniemi

Research output: Contribution to journalArticleScientificpeer-review

16 Citations (Scopus)

Abstract

Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.
Original languageEnglish
Pages (from-to)169-173
JournalCellular Oncology
Volume27
Issue number3
Publication statusPublished - 2005
MoE publication typeA1 Journal article-refereed

Fingerprint

Nonsense Mediated mRNA Decay
Neoplasm Genes
Microarray Analysis
Genome
Mutation
Genes
Prostatic Neoplasms
Cell Line
Comparative Genomic Hybridization
Nonsense Codon
Tumor Suppressor Genes
Neoplasms
Therapeutics
Research

Keywords

  • NMD
  • microarray
  • mutation
  • tumor suppressor gene

Cite this

Wolf, M., Edgren, H., Muggerud, A., Kilpinen, S., Huusko, P., Sørlie, T., ... Kallioniemi, O. (2005). NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cellular Oncology, 27(3), 169-173.
Wolf, Maija ; Edgren, Henrik ; Muggerud, Aslaug ; Kilpinen, Sami ; Huusko, Pia ; Sørlie, Therese ; Mousses, Spyro ; Kallioniemi, Olli. / NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. In: Cellular Oncology. 2005 ; Vol. 27, No. 3. pp. 169-173.
@article{a36c85f92071461fbc75194c9005c99a,
title = "NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer",
abstract = "Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8{\%} of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.",
keywords = "NMD, microarray, mutation, tumor suppressor gene",
author = "Maija Wolf and Henrik Edgren and Aslaug Muggerud and Sami Kilpinen and Pia Huusko and Therese S{\o}rlie and Spyro Mousses and Olli Kallioniemi",
year = "2005",
language = "English",
volume = "27",
pages = "169--173",
journal = "Analytical Cellular Pathology",
issn = "2210-7177",
publisher = "Hindawi",
number = "3",

}

Wolf, M, Edgren, H, Muggerud, A, Kilpinen, S, Huusko, P, Sørlie, T, Mousses, S & Kallioniemi, O 2005, 'NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer', Cellular Oncology, vol. 27, no. 3, pp. 169-173.

NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. / Wolf, Maija (Corresponding Author); Edgren, Henrik; Muggerud, Aslaug; Kilpinen, Sami; Huusko, Pia; Sørlie, Therese; Mousses, Spyro; Kallioniemi, Olli.

In: Cellular Oncology, Vol. 27, No. 3, 2005, p. 169-173.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer

AU - Wolf, Maija

AU - Edgren, Henrik

AU - Muggerud, Aslaug

AU - Kilpinen, Sami

AU - Huusko, Pia

AU - Sørlie, Therese

AU - Mousses, Spyro

AU - Kallioniemi, Olli

PY - 2005

Y1 - 2005

N2 - Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.

AB - Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a “mutatomics” screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.

KW - NMD

KW - microarray

KW - mutation

KW - tumor suppressor gene

UR - http://doi.org/10.1155/2005/478316

M3 - Article

VL - 27

SP - 169

EP - 173

JO - Analytical Cellular Pathology

JF - Analytical Cellular Pathology

SN - 2210-7177

IS - 3

ER -

Wolf M, Edgren H, Muggerud A, Kilpinen S, Huusko P, Sørlie T et al. NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cellular Oncology. 2005;27(3):169-173.